Belimumab, a humanized antibody against ... leading to a marked deficiency in late-transitional (T2) B cells, naive follicular B cells, and marginal-zone B cells. 2 However, the development ...

Healio sat down with Stockfelt to discuss the limitations of rituximab, the optimal SLE populations for B-cell depletion and the future of personalized medicine in the disease. Healio: Why did you ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...